US 12,168,024 B2
Use of functionalised chitosan in the treatment of inflammatory/fibrotic pathologies of the respiratory tract and hepatic pathologies
Lanfranco Callegaro, Como (IT); and Giulio Bianchini, Como (IT)
Assigned to GLYCOCORE PHARMA, Como (IT)
Appl. No. 18/556,096
Filed by GLYCOCORE PHARMA SRL, Como (IT)
PCT Filed Apr. 19, 2022, PCT No. PCT/IB2022/053638
§ 371(c)(1), (2) Date Oct. 19, 2023,
PCT Pub. No. WO2022/224131, PCT Pub. Date Oct. 27, 2022.
Claims priority of application No. 102021000010187 (IT), filed on Apr. 22, 2021.
Prior Publication US 2024/0100084 A1, Mar. 28, 2024
Int. Cl. A61K 31/722 (2006.01); A61K 31/136 (2006.01); A61K 31/137 (2006.01); A61K 31/4178 (2006.01); A61K 31/46 (2006.01); A61K 31/4745 (2006.01); A61K 31/522 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/722 (2013.01) [A61K 31/136 (2013.01); A61K 31/137 (2013.01); A61K 31/4178 (2013.01); A61K 31/46 (2013.01); A61K 31/4745 (2013.01); A61K 31/522 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 47/36 (2013.01); A61K 47/38 (2013.01); A61P 31/14 (2018.01)] 15 Claims
 
1. A method of treating pathologies of the respiratory tract or hepatic pathologies, wherein said pathologies are characterized by inflammation and/or fibrosis, the method comprising the step of
administering to a subject in need thereof an effective amount of a functionalized chitosan, or a salt thereof, as anti-inflammatory and anti-fibrotic agent, said functionalized chitosan being a chitosan wherein at least 20% of D-glucosamine units have the formula (I):

OG Complex Work Unit Chemistry
where R is a moiety of formula (1):

OG Complex Work Unit Chemistry
wherein Z1 is —CH2— or —CO—,
Z2 is —OH, or —NHCOCH3,
Z3 is H, monosaccharide, disaccharide, or oligosaccharide,
or R is a moiety of formula (2):

OG Complex Work Unit Chemistry
wherein Z4 is —CH—,
Z5 and Z6 are, independently of each other, H, monosaccharide, disaccharide, or oligosaccharide.